Michigan insurers seek premium hikes as demand for diet drugs soars

Ozempic was originally approved by the FDA to treat people with type 2 diabetes who are at risk of serious health consequences without medication.  In recent months, there has been a spike in demand for Ozempic, or semaglutide, due to its weight-loss benefits, which has led to shortages.  Some doctors prescribe Ozempic off-label to treat obesity.

Michigan health insurers are looking to raise premiums again next year, with rising demand for expensive diabetes and weight-loss drugs like Ozempic and Wegovy contributing to what they see as needed rate hikes. A report from the Michigan Department of Insurance and Financial Services, which reviews and approves insurer rates, shows health insurance companies are … Read more